Literature DB >> 15660480

The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation.

Jerry Avorn1.   

Abstract

Answering the demanding questions asked of pharmacotherapy in the 21st century will require more reliance on the disciplines of pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology can help assess patterns and appropriateness of drug utilisation, provide explanations for poor compliance, quantify the frequency and severity of side effects, and aid in the design and evaluation of interventions to improve drug use and outcomes. Pharmacoeconomics can help determine whether a new costlier product offers sufficient clinical advantage over its predecessors to justify the increased cost. Taken together, pharmacoepidemiology and pharmacoeconomics represent the next logical step in the evolution of medication assessment; their judicious deployment can help ensure both access to new medicines and innovation.

Entities:  

Mesh:

Year:  2004        PMID: 15660480     DOI: 10.2165/00019053-200422002-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.

Authors:  S R Hill; A S Mitchell; D A Henry
Journal:  JAMA       Date:  2000-04-26       Impact factor: 56.272

2.  Quality indicators for appropriate medication use in vulnerable elders.

Authors:  E L Knight; J Avorn
Journal:  Ann Intern Med       Date:  2001-10-16       Impact factor: 25.391

3.  Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center.

Authors:  D H Solomon; L Van Houten; R J Glynn; L Baden; K Curtis; H Schrager; J Avorn
Journal:  Arch Intern Med       Date:  2001 Aug 13-27

4.  A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes.

Authors:  J Avorn; S B Soumerai; D E Everitt; D Ross-Degnan; M H Beers; D Sherman; S R Salem-Schatz; D Fields
Journal:  N Engl J Med       Date:  1992-07-16       Impact factor: 91.245

5.  Internet marketing of herbal products.

Authors:  Charles A Morris; Jerry Avorn
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

6.  Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture.

Authors:  P S Wang; R L Bohn; R J Glynn; H Mogun; J Avorn
Journal:  Am J Psychiatry       Date:  2001-06       Impact factor: 18.112

7.  An economic evaluation of activated protein C treatment for severe sepsis.

Authors:  Braden J Manns; Helen Lee; Christopher James Doig; David Johnson; Cam Donaldson
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

9.  Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?

Authors:  Daniel H Solomon; Sebastian Schneeweiss; Robert J Glynn; Raisa Levin; Jerry Avorn
Journal:  Am J Med       Date:  2003-12-15       Impact factor: 4.965

10.  A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.

Authors:  S C Kalish; J H Gurwitz; H M Krumholz; J Avorn
Journal:  J Gen Intern Med       Date:  1995-06       Impact factor: 5.128

View more
  1 in total

Review 1.  Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.

Authors:  Christine Y Lu
Journal:  Clin Rheumatol       Date:  2009-02-04       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.